Matches in SemOpenAlex for { <https://semopenalex.org/work/W2317788459> ?p ?o ?g. }
Showing items 1 to 72 of
72
with 100 items per page.
- W2317788459 endingPage "A19" @default.
- W2317788459 startingPage "A19.1" @default.
- W2317788459 abstract "<h3>Background</h3> Neuromyelitis optica (NMO) is a severe inflammatory disorder of the central nervous system. In the majority of patients, the disease is associated with pathogenic antibodies to aquaporin-4 (AQP4) and is recurrent. Treatment is aimed at relapse prevention. Azathioprine is often used first line but does not work in all patients and is often not tolerated. Alternative treatments are needed. Methotrexate is a folate antagonist used widely in rheumatoid arthritis, psoriasis and inflammatory bowel disease. In the UK, it is also used for myasthenia gravis. <h3>Methods</h3> We describe our experience of methotrexate in 14 cases of relapsing AQP4 antibody-positive NMO. <h3>Results</h3> Eleven patients were females, three were males. Median disease duration prior to initiation of methotrexate was 72 months (range 3–192). Three patients were treatment naïve. The mean number of NMO attacks prior to starting methotrexate was 5.3 and mean pre-treatment annualised relapse rate (ARR) was 2.3. Median duration of treatment was 22 months (range 6–84) and mean ARR during treatment was 0.42. Thirteen patients experienced a reduction in ARR on methotrexate and six of these had no attacks. EDSS stabilised or improved in 11 patients. No serious adverse effects occurred. <h3>Conclusion</h3> Methotrexate was well tolerated and reduced relapse rates in the majority of patients and may therefore be a suitable alternative to azathioprine in AQP4 antibody-positive NMO." @default.
- W2317788459 created "2016-06-24" @default.
- W2317788459 creator A5006100482 @default.
- W2317788459 creator A5036881488 @default.
- W2317788459 creator A5040657059 @default.
- W2317788459 creator A5046837181 @default.
- W2317788459 creator A5069974394 @default.
- W2317788459 creator A5070164562 @default.
- W2317788459 date "2012-11-01" @default.
- W2317788459 modified "2023-09-27" @default.
- W2317788459 title "METHOTREXATE MAY BE AN ALTERNATIVE TO AZATHIOPRINE IN NEUROMYELITIS OPTICA WITH AQUAPORIN-4 ANTIBODIES" @default.
- W2317788459 doi "https://doi.org/10.1136/jnnp-2012-304200a.70" @default.
- W2317788459 hasPublicationYear "2012" @default.
- W2317788459 type Work @default.
- W2317788459 sameAs 2317788459 @default.
- W2317788459 citedByCount "0" @default.
- W2317788459 crossrefType "journal-article" @default.
- W2317788459 hasAuthorship W2317788459A5006100482 @default.
- W2317788459 hasAuthorship W2317788459A5036881488 @default.
- W2317788459 hasAuthorship W2317788459A5040657059 @default.
- W2317788459 hasAuthorship W2317788459A5046837181 @default.
- W2317788459 hasAuthorship W2317788459A5069974394 @default.
- W2317788459 hasAuthorship W2317788459A5070164562 @default.
- W2317788459 hasConcept C126322002 @default.
- W2317788459 hasConcept C159654299 @default.
- W2317788459 hasConcept C197934379 @default.
- W2317788459 hasConcept C203014093 @default.
- W2317788459 hasConcept C2776760755 @default.
- W2317788459 hasConcept C2777575956 @default.
- W2317788459 hasConcept C2779134260 @default.
- W2317788459 hasConcept C2779383735 @default.
- W2317788459 hasConcept C2780479503 @default.
- W2317788459 hasConcept C2780564577 @default.
- W2317788459 hasConcept C2781059491 @default.
- W2317788459 hasConcept C2781137167 @default.
- W2317788459 hasConcept C71924100 @default.
- W2317788459 hasConcept C90924648 @default.
- W2317788459 hasConceptScore W2317788459C126322002 @default.
- W2317788459 hasConceptScore W2317788459C159654299 @default.
- W2317788459 hasConceptScore W2317788459C197934379 @default.
- W2317788459 hasConceptScore W2317788459C203014093 @default.
- W2317788459 hasConceptScore W2317788459C2776760755 @default.
- W2317788459 hasConceptScore W2317788459C2777575956 @default.
- W2317788459 hasConceptScore W2317788459C2779134260 @default.
- W2317788459 hasConceptScore W2317788459C2779383735 @default.
- W2317788459 hasConceptScore W2317788459C2780479503 @default.
- W2317788459 hasConceptScore W2317788459C2780564577 @default.
- W2317788459 hasConceptScore W2317788459C2781059491 @default.
- W2317788459 hasConceptScore W2317788459C2781137167 @default.
- W2317788459 hasConceptScore W2317788459C71924100 @default.
- W2317788459 hasConceptScore W2317788459C90924648 @default.
- W2317788459 hasIssue "Suppl 2" @default.
- W2317788459 hasLocation W23177884591 @default.
- W2317788459 hasOpenAccess W2317788459 @default.
- W2317788459 hasPrimaryLocation W23177884591 @default.
- W2317788459 hasRelatedWork W1966766748 @default.
- W2317788459 hasRelatedWork W2120332428 @default.
- W2317788459 hasRelatedWork W2121588356 @default.
- W2317788459 hasRelatedWork W2121688291 @default.
- W2317788459 hasRelatedWork W2289730974 @default.
- W2317788459 hasRelatedWork W2394123269 @default.
- W2317788459 hasRelatedWork W2397221546 @default.
- W2317788459 hasRelatedWork W2437713098 @default.
- W2317788459 hasRelatedWork W39033728 @default.
- W2317788459 hasRelatedWork W3194590854 @default.
- W2317788459 hasVolume "83" @default.
- W2317788459 isParatext "false" @default.
- W2317788459 isRetracted "false" @default.
- W2317788459 magId "2317788459" @default.
- W2317788459 workType "article" @default.